CLSN - Celsion Corporation
| Previous Close | 1.6000 |
| Open | 1.5800 |
| Bid | 0.0000 x 800 |
| Ask | 4.0800 x 1200 |
| Day's Range | 1.5650 - 1.6400 |
| 52 Week Range | 1.0500 - 2.6300 |
| Volume | 176,393 |
| Avg. Volume | 156,985 |
| Market Cap | 37M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4160 |
| Earnings Date | Nov 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- Simply Wall St.
Should You Be Pleased About The CEO Pay At Celsion Corporation's (NASDAQ:CLSN)
In 2007 Michael Tardugno was appointed CEO of Celsion Corporation (NASDAQ:CLSN). This report will, first, examine the...
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-Nov-19 4:00pm GMT
Q3 2019 Celsion Corp Earnings Call
- GlobeNewswire
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety.
- GlobeNewswire
Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia
Celsion Corporation (CLSN), an oncology drug development company, today announced that results from an independent study of a lyso-thermosensitive liposomal doxorubicin (LTLD) was published in the peer-reviewed publication, International Journal of Hyperthermia showing that real-time fluorescence imaging can visualize uptake of LTLD during delivery, and can predict tumor drug uptake in response to heat. ThermoDox® is Celsion’s heat-activated liposomal formulation of doxorubicin currently in Phase III development for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).
- Simply Wall St.
If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
- GlobeNewswire
Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019
Celsion Corporation (CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2019 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EST on Friday, November 15, 2019. On November 4, 2019 the Company announced that the independent Data Monitoring Committee (iDMC) unanimously recommended the OPTIMA Study continue according to protocol. The recommendation was based on a review of blinded safety and data integrity from 556 patients enrolled in the Company’s multinational, double-blind, placebo-controlled pivotal Phase III study with ThermoDox® plus RFA in patients with HCC.
- GlobeNewswire
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
Celsion Corporation (CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first eight patients enrolled in the ongoing Phase I/II OVATION 2 Study. Based on the DSMB's recommendation, the study will continue as planned and the Company will proceed with completing enrollment in the Phase I portion of the trial. The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly diagnosed patients with Stage III and IV ovarian cancer who will undergo standard neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS).
- GlobeNewswire
Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis. The Pooled HEAT Study Data Demonstrated a Median PFS of 16.8 months While the Latest Pooled OPTIMA Study Data Demonstrates Medium PFS of 17.3 months. LAWRENCEVILLE, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (iDMC) has unanimously recommended the OPTIMA Study continue according to protocol.
- Simply Wall St.
Is Celsion (NASDAQ:CLSN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- GlobeNewswire
Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell the Company’s unused New Jersey net operating losses (NOLs) and R&D tax credits. The exact percentage of NOL’s to be sold will be determined by the NJEDA after reviewing all qualified applications. In 2018, the Company received approval from the NJEDA to sell $11.1 million of its unused New Jersey net operating losses for the tax years 2011 through 2017 and was able to transfer this credit and receive approximately $10.5 million of net cash proceeds in the fourth quarter of 2018.
- GlobeNewswire
Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference
Celsion Corporation (CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019 at 9:00 a.m. Eastern time. Management’s participation will take the form of a “Fireside Chat” and will primarily focus on the Company’s development program for GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer.
- GlobeNewswire
Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference
Celsion Corporation (CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13th Annual Conference of the International Liver Cancer Association (ILCA). Other sponsors included Bayer Healthcare Pharmaceuticals, Inc. and Exelixis, Inc., both of whom provide therapeutics for the treatment of advanced HCC. The symposium’s timing verges on the upcoming meeting of the Data Monitoring Committee’s review of the first interim data for the Company’s Phase III OPTIMA Study of its lead drug candidate, ThermoDox®, to treat HCC.
- Simply Wall St.
Market Sentiment Around Loss-Making Celsion Corporation (NASDAQ:CLSN)
Celsion Corporation's (NASDAQ:CLSN): Celsion Corporation, a development stage oncology drug company, focuses on the...
- GlobeNewswire
Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics
Celsion Corporation (CLSN), an oncology drug-development company, announces that a study from a single site in China titled “Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center” has been published in the Journal of Cancer Research and Therapeutics. The data from this single site at the Peking University Cancer Hospital and Institute in Beijing show an overall survival (OS) improvement of 22.5 months in patients with 3-7 cm unresectable hepatocellular carcinoma (HCC) tumors receiving combined radiofrequency ablation (RFA) and ThermoDox®, compared with the use of RFA alone.
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMT
Q2 2019 Celsion Corp Earnings Call
- GlobeNewswire
Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New.
- GlobeNewswire
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with.
- GlobeNewswire
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
Celsion Corporation (CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics and Gynecology-Division of Gynecologic Oncology at Washington University School of Medicine in St. Louis, led an expert call on the ovarian cancer treatment landscape and emerging opportunities hosted by Oppenheimer & Co. Inc. on August 8th. Dr. Thaker is active in the development of GEN-1, Celsion’s DNA-based, IL-12 immunotherapy for the treatment of ovarian cancer.
- GlobeNewswire
Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference Call on Thursday, August 15, 2019
LAWRENCEVILLE, N.J., Aug. 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
- Zacks
Will Celsion (CLSN) Report Negative Q2 Earnings? What You Should Know
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (CLSN), an oncology drug-development company, announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the first interim analysis will be conducted by the Independent Data Monitoring Committee (iDMC). The Company expects the iDMC meeting to occur by mid-October.
- Simply Wall St.
Before You Buy Celsion Corporation (NASDAQ:CLSN), Consider Its Volatility
If you own shares in Celsion Corporation (NASDAQ:CLSN) then it's worth thinking about how it contributes to the...
- GlobeNewswire
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
Celsion Corporation (CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in the Netherlands has received Institutional Review Board (IRB) approval to begin a Phase I study to determine the safety, tolerability and feasibility of ThermoDox® (lyso-thermosensitive liposomal doxorubicin) in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) hyperthermia and cyclophosphamide therapy for the local treatment of the primary tumor in metastatic breast cancer (mBC).
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-May-19 3:00pm GMT
Q1 2019 Celsion Corp Earnings Call
- ACCESSWIRE
Celsion Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Celsion Corp. (NASDAQ: CLSN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 15, 2019 at 11:00 AM Eastern Time. ...
